EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

Isabel Leroux-Roels, Matthew G Davis, Katie Steenackers, Brandon Essink, Corinne Vandermeulen, Charles Fogarty, Charles P Andrews, Edward Kerwin, Marie-Pierre David, Laurence Fissette, Carline Vanden Abeele, Delphine Collete und 10 weitere

The Journal of Infectious Diseases · 28.03.2023 · 227 (6) · 761-772

DOI: 10.1093/infdis/jiac327 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.07.2022. Verfasst von Isabel Leroux-Roels und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccinology, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline Biologicals SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to investigate safety and immunogenicity of vaccine formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion conformation of RSV fusion protein (RSVPreF3).

Methods

This phase 1/2, randomized controlled, observer-blind study enrolled 48 young adults (YAs; aged 18–40 years) and 1005 older adults (OAs; aged 60–80 years) between January and August 2019. Participants were randomized into equally sized groups to receive 2 doses of unadjuvanted (YAs and OAs) or AS01-adjuvanted (OAs) vaccine or placebo 2 months apart. Vaccine safety and immunogenicity were assessed until 1 month (YAs) or 12 months (OAs) after second vaccination.

Results

The RSVPreF3 vaccines boosted humoral (RSVPreF3-specific immunoglobulin G [IgG] and RSV-A neutralizing antibody) responses, which increased in an antigen concentration-dependent manner and were highest after dose 1. Compared to prevaccination, the geometric mean frequencies of polyfunctional CD4+ T cells increased after each dose and were significantly higher in adjuvanted than unadjuvanted vaccinees. Postvaccination immune responses persisted until end of follow-up. Solicited adverse events were mostly mild to moderate and transient. Despite a higher observed reactogenicity of AS01-containing vaccines, no safety concerns were identified for any assessed formulation.

Conclusions

Based on safety and immunogenicity profiles, the AS01E-adjuvanted vaccine containing 120 μg of RSVPreF3 was selected for further clinical development. Clinical Trials Registration NCT03814590.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanYoung AdultHumansAgedAntibodies, ViralAntibodies, NeutralizingImmunogenicity, Vaccine

Stichwörter der Autor:innen

AS01 adjuvantF proteinRSV neutralizing antibodiescell-mediated immunityrespiratory syncytial virus

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Center for Vaccinology, Ghent University Hospital, Ghent, Belgium.
  • Rochester Clinical Research, Rochester, New York, USA.
  • Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
  • Meridian Clinical Research Omaha, Omaha, Nebraska, USA.
  • Department of Public Health and Primary Care, Leuven University Vaccinology Center, KU Leuven, Leuven, Belgium.
  • Lung and Chest Medical Associates, Spartanburg Medical Research, Spartanburg, South Carolina, USA.

Förderung

  • GlaxoSmithKline Biologicals SA

Zitieren

APA

Leroux-Roels, I., Davis, M. G., Steenackers, K., Essink, B., Vandermeulen, C., Fogarty, C., Andrews, C. P., Kerwin, E., David, M. P., Fissette, L., Vanden Abeele, C., Collete, D., de Heusch, M., Salaun, B., De Schrevel, N., Koch, J., Verheust, C., Dezutter, N., Struyf, F., …, & Hulstrøm, V. (2023). Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. The Journal of Infectious Diseases, 227(6), 761-772. https://doi.org/10.1093/infdis/jiac327

Vancouver

Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, et al. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. The Journal of Infectious Diseases. 2023;227(6):761-772. doi:10.1093/infdis/jiac327

BibTeX
@article{LerouxRoels2023,
  author = {Leroux-Roels, Isabel and Davis, Matthew G and Steenackers, Katie and Essink, Brandon and Vandermeulen, Corinne and Fogarty, Charles and Andrews, Charles P and Kerwin, Edward and David, Marie-Pierre and Fissette, Laurence and Vanden Abeele, Carline and Collete, Delphine and de Heusch, Magali and Salaun, Bruno and De Schrevel, Nathalie and Koch, Juliane and Verheust, Céline and Dezutter, Nancy and Struyf, Frank and Mesaros, Narcisa and Tica, Jelena and Hulstrøm, Veronica},
  title = {Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  volume = {227},
  number = {6},
  pages = {761--772},
  doi = {10.1093/infdis/jiac327}
}
Kostenlos starten →